Zevorcabtagene autoleucel Medicine 07 December 2021 Extended indication In Patients With Relapsed and/or Refractory Multiple Myeloma. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Zevorcabtagene autoleucel Domain Hematology Reason of inclusion New medicine (specialité) Main indication Multiple Myeloma Extended indication In Patients With Relapsed and/or Refractory Multiple Myeloma. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer CARsgen Portfolio holder Mechanism of action Unknown Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Yes Submission date 2024 Expected Registration 2025 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Primary completion datum in december 2022. Heeft wel een weesstatus in de Verenigde Staten. Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Plaatsbepaling ten opzichte van andere behandelingen is nog niet in te schatten. Duration of treatment Frequency of administration Dosage per administration References LUMMICAR STUDY 1 (NCT03975907) Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Gezien de vele behandelopties komen naar schatting maximaal 50 patiënten per jaar hiervoor in aanmerking. Naar de toekomst toe kan CAR-T mogelijk naar eerdere behandellijnen verschuiven, in dat geval zouden meer patiënten in aanmerking komen. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks